Two-drug trial produces two-thirds tumor shrinkage in melanoma

By Amara Osei

Lifileucel plus pembrolizumab shrank tumors in two-thirds of patients with advanced melanoma (the deadliest form of skin cancer, already spread beyond its origin) in an international trial presented at the European Society for Medical Oncology congress in Madrid. British researchers presented the findings in Madrid, where one-third of participants saw their tumors disappear completely on scans, and some achieved stable disease for four years. The report did not state the sample size, trial phase, randomization, median follow-up, or response duration for most participants, which limits interpretation of the headline response rates.

How does the two-stage treatment work?

The sequence uses the patient’s disease-fighting cells, which clinicians extract, multiply in a laboratory, and return through a one-time intravenous infusion. Pembrolizumab follows to block PD-1, a protein checkpoint that tumors can exploit to evade immune detection. The treatment therefore aims for direct cellular attack and broader immune recognition, although the report does not isolate each component’s contribution or provide detailed safety findings.

Only half of patients with advanced melanoma respond to available life-extending treatments, according to the report. Dr Andrew Furness, the trial’s lead investigator, medical oncologist, and skin cancer specialist at the Royal Marsden, said: “Melanoma is one of the few tumour types where even if it has spread across the body, there is a potential for a cure, and this could be it.”

That statement identifies an investigational possibility rather than a demonstrated cure rate; the report supplied no cohort-wide recurrence or overall-survival data. Furness said the combination may deliver its greatest benefit relatively soon after spread and argued that aggressive early treatment could be life-changing as more young people develop cancer. Both propositions await confirmation from the separate earlier-treatment trial.

What happened to Paul Jenner?

Paul Jenner, 59, a father of two, first noticed trouble when a wooden garden fence scraped his upper back. He felt sharp, itchy pain that resolved within hours, but a mole snagged on the wood and came away. The site scabbed and rebled over several months before his general practitioner referred him to a dermatologist, whose biopsy identified melanoma.

Further tests showed disease in his lungs and later his back. He had never used sunbeds, reported no family history of cancer, and rarely exposed his skin to the sun. Those features did not exclude melanoma. Its pigment-producing cells can mutate after ultraviolet damage, while some mutations are present from birth.

He received the combination in August 2024 as one of the first trial participants. At two years, he remains in remission and reports no returning disease. Paul said: “I had growths on my lungs, my back and a couple of other areas doctors were keeping an eye on and they all disappeared following treatment.”

He also described improved physical and mental health and advocates wider NHS access. That favorable course remains one case, not an estimate of benefit for a broader population.

When might the combination reach NHS use?

The combination was expected to receive Medicines and Healthcare products Regulatory Agency approval for NHS use as early as November. Initial access would remain restricted to patients whose other treatments had failed, so the immediate effect would not alter first-line care.

The report gave no approval date, rollout schedule, eligibility criteria, or commissioning terms, making the anticipated timeline a projection rather than an access guarantee. A separate international trial now examines effectiveness and feasibility when the combination is given earlier alongside standard treatment; no results from that study were available.

Can melanoma develop without sun exposure?

Studies cited in the report estimate that one in 10 melanoma cases is unrelated to sun exposure. Non-melanoma skin cancers almost always link to sunlight and ultraviolet radiation, but melanoma can develop in sites that rarely see sunlight. The report identifies acral melanoma as the most common melanoma in this group; it typically affects people of Black or Asian descent.

Acral melanoma occurs on the palms, soles, or beneath fingernails and toenails. It often differs in color from surrounding skin and can resemble a bruise, which may delay recognition. Melanoma begins when pigment-producing cells mutate and multiply uncontrollably. Ultraviolet damage causes most such mutations, while some are present from birth, so low sun exposure does not rule out melanoma.

The report warned that thousands of Britons may overlook warning signs because low sun exposure creates false security. Skin-cancer rates are also rising faster than bowel, breast, prostate, and lung cancer rates, while early detection before deeper skin invasion remains crucial regardless of sun exposure. It did not provide the population or trend data behind those comparisons.

Which warning signs require assessment?

Experts recommend the ABCDE checklist for recognizing melanoma:

• A — asymmetry
• B — irregular borders
• C — changes in color
• D — increasing diameter
• E — evolution or change in appearance over time

Pain, repeated bleeding, or failure to heal warrants medical review. A growing melanoma may ulcerate and bleed, and injury does not itself turn a mole cancerous. An abnormal healing pattern can nonetheless justify examination.

Risk increases with fair skin, freckles, red or blonde hair, severe sunburn history, weakened immunity, numerous moles, atypical moles, or a close relative with melanoma. Around nine in ten cases occur in people without a family history. For men, melanoma most often appears on the back; for women, the legs are more common sites.

Avoiding sunburn, using sun protection during prolonged outdoor exposure, and checking skin regularly can lower risk, although prevention cannot eliminate every case. Cancer Research UK research director Dr Catherine Elliott described the findings as promising, adding that personalized therapy could hold cancer at bay longer for some patients.

The next test is whether earlier treatment improves durable remission and feasibility without unacceptable toxicity. The current findings neither quantify safety nor establish a cure rate. If the earlier-treatment trial and regulatory review confirm benefit, NHS access could expand beyond patients who have exhausted other options.